anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to medicine composition for treating burn wound and a preparation method thereof. The medicine composition consists of angelica dahurica, radix paeoniae rubra, radix scrophulariae, rhubarb, radix rehmanniae, angelica, cortex phellodendri, salivia chinensis, rhizoma coptidis, szechuan lovage rhizome, radix paeoniae alba and vegetable oil. The preparation method comprises the steps: placing the angelica dahurica, the radix paeoniae rubra, the radix scrophulariae, the rhubarb, the radix rehmanniae, the angelica, the cortex phellodendri, the salivia chinensis, the rhizoma coptidis, the szechuan lovage rhizome, the radix paeoniae alba and the vegetable oil into a gauze after oil-immersion, mixing, heating and filtering. The medicine composition belongs to the secret recipe of the pure Chinese Traditional medicine, uses traditional medicine materials as raw materials and is prepared by adopting scientific proportion so as to dredge the channels and collaterals, remove pattogenic heat from the blood and toxic material from the body, activate blood and dissolve stasis, relieve swelling and pain and remove the rotten and let fresh grow, recover energy with biochemical operation, activate metabolism and enhance self-immunity function so that the surface of the wound hurt by the burn wound can obtain regenerative repair. The medicine composition can be used for treating various kinds of fire burn, scalding, trauma, abscess, bedsore, scarring and angiitis, various kinds of skin infections, and the like. Due to no pain for treating the burn injury without skin graft, smooth wound surface treated in third-degree burn injury, no obvious scar, the medicine composition is an external treatment with no toxity, no incitement, no senitization, safe and good healing efficacy, and can be applied to emergency treatment for burn injury.
Successful therapy following viral rebound has been problematic. Intensification of the existing regimen by adding 1 or 2 drugs generally has been avoided. However, successfully adding new drugs to an existing regimen would be advantageous since it would expose the patient to fewer antiretroviral agents in the overall treatment course. Recent evidence suggests that a significant proportion of patients who experience viral rebound while receiving a protease inhibitor (PI) actually have viral rebound with a PI-sensitive virus. Other studies have shown that treatment decisions based on resistance assays result in better virologic outcomes. This trial examines further the effect of resistance assay-directed intensification of a PI-containing antiretroviral regimen on viral load. \[AS PER AMENDMENT 04/03/01: The antiretroviral regimen need not contain a protease inhibitor.\]

Patients are stratified by baseline plasma HIV-1 RNA levels (5,000 copies/ml or less versus greater than 5,000 copies/ml). Patients undergo phenotypic drug resistance testing prior to study entry. Based on the phenotypic results, patients are \[AS PER AMENDMENT 11/9/00: selectively\] randomized equally to 1 of 3 \[AS PER AMENDMENT 11/9/00: 1 of 2\] intensification strategies while remaining on their current, initial \[AS PER AMENDMENT 11/9/00: (background)\] antiretroviral therapy (ART). \[AS PER AMENDMENT 04/03/01: ART need not be initial.\] A patient is excluded from randomization to an arm if that arm contains a drug to which the patient has phenotypic resistance. Arm A adds abacavir (ABC). Arm B adds amprenavir (APV) \[AS PER AMENDMENT 11/9/00: and ritonavir (RTV)\]. Arm C adds didanosine (ddI) plus hydroxyurea (HU). \[AS PER AMENDMENT 11/9/00: Arm C has been discontinued.\] A patient's HIV must be sensitive to at least 3 drugs. \[AS PER AMENDMENT 11/9/00: Each patient must be taking at least 3 drugs to which his/her HIV isolate is sensitive, including ABC or APV and at least 2 other drugs that are part of the current, initial (background) ART. If phenotypic resistance testing at screening indicates resistance to a nucleoside reverse transcriptase inhibitor (NRTI) drug in the patient's current, initial (background) ART, then the local investigator may choose to discontinue that drug. However, the patient and local investigator may choose to continue the drug but it will not be considered an active drug per this protocol.\] \[AS PER AMENDMENT 04/03/01: ART need not be initial.\] Patients have regular clinic visits for physical exams and blood tests, including CD4 and CD8 cell counts, plasma HIV-1 RNA assays, and tests for pharmacokinetic variability. In the event of viral rebound of 500 copies/ml or more at Week 12 or later, phenotypic/genotypic drug resistance is assayed. In addition, phenotypic drug resistance is assayed at the primary endpoint (Week 24) and at the end of treatment (Week 48) on all patients.
PURPOSE:To obtain the titled pigment having excellent stability, appearance and touch, by dispersing titanium dioxide-coated mica in water, adjusting its pH and adding an aq. soln. contg. an oxidizing agent and a ferrous salt to precipitate tri-iron tetroxide on the surfaces of mica particles. CONSTITUTION:Titanium dioxide-coated mica is dispersed in water and the pH of the dispersion is adjusted to 7-12 by adding a base (e.g. ammonium hydroxide or potassium hydroxide). At the same time, an aq. soln. contg. an oxidizing agent (e.g. sodium nitrate or potassium chlorate) and a ferrous salt (e.g. ferrous sulfate or ferrous chloride) is slowly added thereto to precipitate tri-iron tetroxide on the surfaces of the titanium dioxide-coated mica particles, thus obtaining a black pearlescent pigment and an iron oxide-coated surface. When the pigment is heat-treated at 500-1,000 deg.C in the air, a red pearlescent pigment can be obtd.
Antisecretory Activity

After oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours. Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours. The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal H+/K+ ATPase enzyme. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days.

Results from numerous studies of the antisecretory effect of multiple doses of 20 mg and 40 mg of omeprazole in healthy subjects and patients are shown below. The “max” value represents determinations at a time of maximum effect (2 to 6 hours after dosing), while “min” values are those 24 hours after the last dose of omeprazole.
Exposure to the neurotoxin trimethyltin (TMT) selectively induces hippocampal neuronal injury and astrocyte activation accompanied with resultant neuroinflammation, which causes severe behavioral, cognitive, and memory impairment. A large body of evidence suggests that flaxseed oil (FSO), as one of the richest sources of essential omega-3 fatty acids, i.e., α-linolenic acids (ALA), displays neuroprotective properties. Here, we report the preventive effects of dietary FSO treatment in a rat model of TMT intoxication. The administration of FSO (1 mL/kg, orally) before and over the course of TMT intoxication (a single dose, 8 mg/kg, i.p.) reduced hippocampal cell death, prevented the activation of astrocytes, and inhibited their polarization toward a pro-inflammatory/neurotoxic phenotype. The underlying protective mechanism was delineated through the selective upregulation of BDNF and PI3K/Akt and the suppression of ERK activation in the hippocampus. Pretreatment with FSO reduced cell death and efficiently suppressed the expression of inflammatory molecules. These beneficial effects were accompanied by an increased intrahippocampal content of n-3 fatty acids. In vitro, ALA pretreatment prevented the TMT-induced polarization of cultured astrocytes towards the pro-inflammatory spectrum. Together, these findings support the beneficial neuroprotective properties of FSO/ALA against TMT-induced neurodegeneration and accompanied inflammation and hint at a promising preventive use of FSO in hippocampal degeneration and dysfunction.
The large-scale production of psilocybin. More particularly, it relates to a method of obtaining high-purity crystalline psilocybin, particularly, in the form of Polymorph A. Also, a method for the manufacture of psilocybin and formulations containing psilocybin. Crystalline psilocybin, Polymorph A or Polymorph A’, characterised by one or more of: a. peaks in an XRPD diffractogram at 11.5, 12.0 and 14.5 °2θ±0.1°2θ; b. peaks in an XRPD diffractogram at 11.5, 12.0 and 14.5 °2θ±0.1°2θ, further characterised by at least one further peak at 19.7, 20.4, 22.2, 24.3 or 25.7 °2θ±0.1°2θ; c. an XRPD diffractogram as substantially illustrated in Figure 7a or 7b; or d. an endothermic event in a DSC thermogram having an onset temperature of 205-220°C substantially as illustrated in Figure 8a or 8b. The crystalline psilocybin may be formulated into pharmaceutical formulation, preferably an oral dosage form. The formulation may comprise an excipient(s), particularly microcrystalline cellulose or starch. The crystalline psilocybin or formulation thereof may be used in treating a central nervous disorder, more preferably in treating drug resistant depression. Alternatively, a method for large-scale manufacture of psilocybin comprising subjecting psilocybin to a water-crystallisation step, with controlled drying, to produce a crystalline psilocybin Polymorph A.
PURPOSE:To obtain a preventive agent against arrhythmia, containing superoxide dismutase modified with a poly(oxyalkylene) as an active ingredient, having excellent pharmacological activity and capable of prevention and prophylaxis of human arrhythmia. CONSTITUTION:A preventive agent against arrhythmia containing, e.g. a modified superoxide dismutase (hereinafter abbreviated to SOD) having a skeleton in which superoxide dismutase is linked to both terminals of a poly(oxyalkylene) molecules as an active ingredient. Active oxygen is a cause for onset of arrhythmia, necrosis of myocardia, etc., and the SOD is regarded as inhibiting the onset of the arrhythmia. Although effectiveness of chemical modification is unknown, the purpose as a medicine can be attained by modifying the SOD with the poly(oxyalkylene). The SOD may be derived from any of humans and mammals, such as cattle or horse.
The invention discloses a composition for treating esophageal cancer. The composition comprises the following raw materials in parts by weight: one live toad, 0.8-1.3 parts of borneol, 0.8-1.3 parts of borax, one egg, and a proper amount of mud. The invention also discloses preparation and taking methods of the composition for treating esophageal cancer. The live toad is capable of detoxifying, removing stasis, removing stagnation and promoting diuresis. The borneol is capable of help understand things and improve eyesight, and alleviating edema and relieving pain. The borax is capable of clearing heat and relieving phlegm, detoxifying and preventing decaying. The egg is capable of calming nerves, tranquilizing mind and regulating medicinal nature. The composition components cooperate with each other, and the composition has a significant effect on treatment of esophageal cancer, has the advantages of easily available raw materials, low price, and convenience in use, and is suitable for home making.
In arm 2 patients will receive nutritional support which will provide glutamine 0.5g/kg/day. Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients.
BACKGROUND: Pathologic scars, including keloids and hypertrophic scars, represent a common form of exaggerated cutaneous scarring that is difficult to prevent or treat effectively. Additionally, the pathobiology of pathologic scars remains poorly understood. We aim at investigating the impact of TEM1 (also known as endosialin or CD248), which is a glycosylated type I transmembrane protein, on development of pathologic scars.
METHODS: To investigate the expression of TEM1, we utilized immunofluorescence staining, Western blotting, and single-cell RNA-sequencing (scRNA-seq) techniques. We conducted in vitro cell culture experiments and an in vivo stretch-induced scar mouse model to study the involvement of TEM1 in TGF-β-mediated responses in pathologic scars.
RESULTS: The levels of the protein TEM1 are elevated in both hypertrophic scars and keloids in comparison to normal skin. A re-analysis of scRNA-seq datasets reveals that a major profibrotic subpopulation of keloid and hypertrophic scar fibroblasts greatly expresses TEM1, with expression increasing during fibroblast activation. TEM1 promotes activation, proliferation, and ECM production in human dermal fibroblasts by enhancing TGF-β1 signaling through binding with and stabilizing TGF-β receptors. Global deletion of Tem1 markedly reduces the amount of ECM synthesis and inflammation in a scar in a mouse model of stretch-induced pathologic scarring. The intralesional administration of ontuxizumab, a humanized IgG monoclonal antibody targeting TEM1, significantly decreased both the size and collagen density of keloids.
CONCLUSIONS: Our data indicate that TEM1 plays a role in pathologic scarring, with its synergistic effect on the TGF-β signaling contributing to dermal fibroblast activation. Targeting TEM1 may represent a novel therapeutic approach in reducing the morbidity of pathologic scars.
BACKGROUND: Cancer pain remains highly prevalent and persistent throughout survivorship, and it is crucial to investigate the potential of leveraging the advanced features of mobile health (mHealth) apps to empower individuals to self-manage their pain.
OBJECTIVE: This review aims to comprehensively understand the acceptability, users' experiences, and effectiveness of mHealth apps in supporting cancer pain self-management.
METHODS: We conducted an integrative review following Souza and Whittemore and Knafl's 6 review processes. Literature was searched in PubMed, Scopus, CINAHL Plus with Full Text, PsycINFO, and Embase, from 2013 to 2023. Keywords including "cancer patients," "pain," "self-management," "mHealth applications," and relevant synonyms were used in the search. The Johns Hopkins research evidence appraisal tool was used to evaluate the quality of eligible studies. A narrative synthesis was conducted to analyze the extracted data.
RESULTS: A total of 20 studies were included, with the overall quality rated as high (n=15) to good (n=5). Using mHealth apps to monitor and manage pain was acceptable for most patients with cancer. The internal consistency of the mHealth in measuring pain was 0.96. The reported daily assessment or engagement rate ranged from 61.9% to 76.8%. All mHealth apps were designed for multimodal interventions. Participants generally had positive experiences using pain apps, rating them as enjoyable and user-friendly. In addition, 6 studies reported significant improvements in health outcomes, including enhancement in pain remission (severity and intensity), medication adherence, and a reduced frequency of breakthrough pain. The most frequently highlighted roles of mHealth apps included pain monitoring, tracking, reminders, education facilitation, and support coordination.
CONCLUSIONS: mHealth apps are effective and acceptable in supporting pain self-management. They offer a promising multi-model approach for patients to monitor, track, and manage their pain. These findings provide evidence-based insights for leveraging mHealth apps to support cancer pain self-management. More high-quality studies are needed to examine the effectiveness of digital technology-based interventions for cancer pain self-management and to identify the facilitators and barriers to their implementation in real-world practice.
Data suggest that individual Cognitive Behavior Therapy (CBT) is effective in reducing anxiety disorders in children. The incorporation of parents and peers in a CBT treatment program also has been found to be effective in reducing anxiety symptoms, because a child's environment (i.e., parents, peers) affect the development, course, and outcome of childhood anxiety and functional status. Children and their parents will be randomly assigned to one of two treatment conditions: Family/Parents CBT (FCBT) or Peer/Group CBT (GCBT) for 14 to 16 weekly sessions. Parent-child relationships are the focus of FCBT. Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children. Children in the GCBT group will be trained to be more helpful and positive toward other children through role-playing activities. Interviews, questionnaires, and behavior observation tasks will be used to assess participants. All participants will be assessed at pretreatment, post-treatment, and at yearly follow-up visits. The first set of hypotheses that will be tested is that FCBT will produce significantly greater specific effects on parenting skills and parent-child relationships than on child social skills and peer-child relationships. GCBT, on the other hand, will produce significantly greater specific effects on child social skills and peer-child relationships than on parenting skills and parent-child relationships. The second set of hypotheses will test whether or not it is the changes that are produced on these variables that mediate treatment response. Thus, the second set of hypotheses that will be tested is that parenting skills, parent-child relationships, child social skills and/or peer-child relationships will be significant mediators of treatment response, i.e., anxiety reduction
1,217,365. Medicines &c for ruminants. JOHN LABATT Ltd. 8 Feb., 1968 [23 Feb., 1967], No. 6277/68. Heading A5B. An additive to ruminant feedstuffs comprises particles containing one or more amino acids coated with a continuous film of a material which passes substantially unchanged through the rumen but which releases the amino acids posterior to the omasum, the particles having a density in the range 0.8 to 2.0 and a size of 200 to 2000 microns. The coating may be of rice bran wax or a fatty acid triglyceride and the particles may be made by conventional procedures such as fluidized bed coating, prilling or centrifugal extrusion encapsulation.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, dentistry. Substance of the method for making a tooth consists in placing into a bearing carrier a first cell mass substantially consisting of cells of one of the following species: mesenchymal cells originated from amnion discharges as delivery excrements, or epithelial cells, and a second cell mass substantially consisting of cells of the other species among said mesenchymal cells originated from amnion discharges as delivery excrements, and epithelial cells wherein said first and second cell masses are not mixed, but contact each other tightly. Said epithelial cells are originated from the following sources: dental germ of third molar, skin, mucosa or gingiva. Said first and second cell masses are cultured in the bearing carrier. The method of treating or care in various symptoms associated with dental loss or damage is implemented by tooth and/or periodont tissue grafting into the place of dental loss and/or damage. Additionally, it involves the stages of tooth alignment so that to provide the same direction as the other tissue in the place of grafting. ^ EFFECT: use of the invention provides making the tooth cells of which are arranged in a certain order so that the restored tooth functions as tissue thereby ensuring higher clinical effectiveness. ^ 1 ex, 3 dwg
General treatment of hypercalcemia (greater than 1 mg/dL above the upper limit of the normal range) consists of immediate discontinuation of Rocaltrol therapy, institution of a low-calcium diet and withdrawal of calcium supplements. Serum calcium levels should be determined daily until normocalcemia ensues. Hypercalcemia frequently resolves in 2 to 7 days. When serum calcium levels have returned to within normal limits, Rocaltrol therapy may be reinstituted at a dose of 0.25 mcg/day less than prior therapy. Serum calcium levels should be obtained at least twice weekly after all dosage changes and subsequent dosage titration. In dialysis patients, persistent or markedly elevated serum calcium levels may be corrected by dialysis against a calcium-free dialysate.
Risk Summary

No studies have been conducted with the use of ibuprofen and famotidine tablet in lactating women. Limited data from published literature report famotidine is present in human milk in low amounts. Published literature also reports the presence of ibuprofen in human milk in low amounts. No information is available on the effects of famotidine or ibuprofen on milk production or on a breastfed infant. Famotidine is present in the milk of lactating rats (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ibuprofen and famotidine tablet and any potential adverse effects on the breastfed infant from ibuprofen and famotidine tablet or from the underlying maternal condition.

Data

Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of at least 300 times the usual human dose of famotidine.
There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
Nasal congestion is one of the most common complaints in Otorhinolaryngology medicine. One of the most common causes of this is the collapse or blockage of the Internal Nasal Valve (INV). The internal nasal valve is the narrowest part of the airway and creates the greatest resistance to airflow. Its most important function is to regulate the inspiratory airflow. It is determined by the angle formed between the caudal part of the upper lateral cartilage and the nasal septal cartilage. This angle normally varies between 9-15 degrees. The tip of the inferior turbinate and the tissues surrounding the piriform aperture may affect this area. When this angle is less than 9 degrees, the valve collapses in inspiration. The internal nasal valve region should be evaluated in every patient complaining of nasal congestion. the investigators planned to radiologically examine the improvement in the internal nasal valve angle of the patients we operated on.
Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
The invention provides a natural plant extract. The natural plant extract is applied to prepare a drug of preventing and treating nosema apis as follows: by taking grape skin as a raw material, leaching by an alcohol solvent, and extracting a pasty substance by virtue of processes such as ultrasonic crushing and rotary evaporation; then, preparing the pastry substance into a grape skin extract syrup mixture in certain proportion, so as to prepare the drug of preventing and treating nosema apis. During use, a feeder is filled with the natural plant extract for enabling bees infected with the microsporidia to freely take food, and acted to the bees and the microsporidia, so that the effects of effectively preventing and treating the nosema apis are achieved. The natural plant extract has no toxic or side effects on bees and is rich in flavonoid compounds such as anthocyanin as well as substances such as tannin and cellulose. The control effect on the nosema apis is good, the raw material source of the drug is wide, easily available, simple to prepare and low in cost. Moreover, the natural plant is free of pollution on bee products and environment, and is a healthy, environment-friendly, ecological and efficient new way of preventing and treating nosema apis.